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ABSTRACT 
 
Preeclampsia remains the leading cause of maternal and neonatal morbidity and mortality 
worldwide. The imbalance of interactions between the placenta, immunity and the maternal 
cardiovascular system also plays a role in preeclampsia. Early onset preeclampsia (POD) and 
advanced onset preeclampsia (POL) are thought to have different pathomechanisms, causing 
different clinical symptoms. One theory of preeclampsia is the occurrence of endothelial 
dysfunction. Endocan as a specific endothelial protein is also thought to have an effect. Various 
studies on the role of Endocan in cardiovascular disease have also been carried out, while its 
role in preeclampsia that occurs in pregnant women is still very minimal. This study aims to 
determine the role of Endocan as a specific endothelial protein in preeclampsia. The study 
design was cross-sectional. A total of 72 subjects (24 subjects each in the POD, POL and 
normotensive pregnancy groups) were selected by consecutive sampling. Enzym Linked 
Immunoabsorbant Assay (ELISA) was performed to assess the Endocan concentration. In 
general, there is no significant difference in the characteristics of research subjects. Endocan 
concentrations were found to be higher in the POD group, while in the POL and normotensive 
pregnancy groups there was no significant difference. Endocan can be considered as a potential 
marker of preeclampsia, especially early onset. 
 
Keywords: Endocan, endothelium, preeclampsia 
1. INTRODUCTION 
Preeclampsia is a specific disorder that 
occurs in pregnancy, characterized by 
hypertension and proteinuria after 20 
weeks' gestation, in women who were 
previously normotensive (Walker, 2000; 
Robert, 2001). Preeclampsia affects 2–8% 
of pregnancies, and is a major cause of 
maternal and fetal morbidity and mortality, 
as well as causes the second largest 
maternal mortality worldwide (Huppertz B, 
2008). The etiology of preeclampsia 
remains unclear, but it is thought that 
various factors, including placental 
ischemia, endothelial cell dysfunction, 
vasospasm, inflammation, inadequate  
 
 
angiogenesis and oxidative stress play a 
role in its development. Disruption of 
trophoblast invasion in early pregnancy 
will cause placental dysfunction and 
damage to the endothelium of blood 
vessels. In endothelial dysfunction there is 
an imbalance between humoral and cellular 
factors that will affect the structure and 
function of the endothelial wall. Risk 
factors that influence the occurrence of 
endothelial dysfunction include 
hypertension, dyslipidemia, smoking, age 
and obesity (Petrák et al, 2006; Widlansky 
et al, 2003; Ganz et al, 2003). In 
preeclampsia, endothelial dysfunction, if it 
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continues, will eventually affect the 
maternal hemodynamic system and lead to 
changes in maternal heart morphometry, 
especially in women who already have risk 
factors in their blood vessels. 
Circulating Endothelial Cells (CEC) 
and other endothelial cell factors are often 
used as markers of endothelial cell 
activation / dysfunction. Several previous 
studies have shown an increase in CEC and 
other markers of endothelial cell damage 
such as soluble vascular cell adhesion 
molecule-1 (sVCAM-1), E-selectin and 
Endocan (Possomato-vieira & Khalil 
2016).  
Endocan is a specific endothelial cell 
molecule in humans, which was first 
discovered in 1999. Endocan is released by 
vascular endothelium into the circulation 
and plays an important role in regulating 
various processes, including adhesion, 
inflammation, and tumor progression. 
Endocan levels in serum will increase in 
several conditions related to endothelial 
activation or dysfunction (Yuksel et al, 
2015). 
In preeclampsia, there is extensive 
inflammation of the various organs 
involved, which will lead to excretion 
endocan. Endocan is a new marker that is 
thought to be associated with the incidence 
of hypertension. The role of Endocan as a 
marker in the incidence of hypertension has 
been tested in several studies, but the role 
of Endocan as a response to endothelial 
dysfunction in preeclampsia is still very 
limited. 
Based on the time of diagnosis, there 
are terms early onset preeclampsia (<34 
weeks) and late onset preeclampsia (> 34 
weeks). Early onset preeclampsia is said to 
be associated with poor placentation, 
IUGR, and long-term cardiovascular 
effects than late-onset preeclampsia, whose 
pathogenesis is more related to maternal 
metabolic and cardiovascular factors that 
can induce endothelial dysfunction. The 
endothelium is the target organ in the 
pathophysiology of preeclampsia. 
Therefore, it is estimated that the maternal 
serum concentration of Endocan can be 
used as a marker of preeclampsia. 
 
 
2. METHOD 
This study is a cross-sectional 
comparative study with a screening 
technique, namely consecutive sampling. 
The research was conducted at Muhammad 
Hoesin Hospital Palembang and RS 
Hermina Palembang from October 2017 to 
January 2018. In this study, the population 
was all pregnant women who came with 
severe preeclampsia to Muhammad Hoesin 
Hospital Palembang and Hermina 
Palembang Hospital during the study 
period. The inclusion criteria were divided 
into two groups, namely the preeclampsia 
group and the normotensive pregnant 
women group. In the preeclampsia group 
the inclusion criteria were pregnant women 
who had severe preeclampsia (POD: 
gestational age> 20 weeks - <34 weeks; 
POL: gestational age> 34 weeks), single 
live intrauterine pregnancy, normal body 
temperature, and willing to participate in 
the study with signed an informed consent. 
Whereas for the normotension group, the 
inclusion criteria were gestational age> 37 
weeks, not yet in labor, normotension, no 
history of cardiovascular disease and no 
history of other medical disorders. Subjects 
with a history of heart disease or currently 
suffering from cardiovascular disease, 
previous history of kidney disease, a history 
of liver dysfunction, a history of 
haematological disease and coagulation 
disorders, and using anticoagulant drugs, 
chronic antihypertensive and thrombolytic 
or not willing to be included in the study 
were excluded from the study. 
The sample size was calculated using 
the numerical data sample size estimation 
formula for the mean difference of the 2 
independent groups. There were 72 
samples in this study, with the distribution 
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of each of the 24 samples in the POD, POL 
and normotensive groups. 
Each study subject was subjected to 
standard examinations according to the 
preeclampsia protocol (blood pressure, 
proteinuria, complete blood chemistry, 
liver and kidney function tests and 
assessment of neurological deficits). 
Subjects who meet the inclusion criteria 
will then be given informed consent to 
collect blood for serum Endocan 
examination. 10 mL of venous blood 
samples for research subjects were taken 
for Endocan examination. The blood 
sample taken was inserted into an 
ethylenediamine tetracetic acid (EDTA) 
tube for DPL examination, a serum 
separator tube (SST) tube for PP 13 and 
Endocan examinations. Blood samples (for 
PP 13 and Endocan were centrifuged at 
1500 g for 10 minutes and stored at -80oC). 
Measurement of maternal endocan serum 
concentrations was carried out using the 
ELISA technique using the Human 
Endothelial-Cell Specific Molecule-1 
(ESM-1) ELISA kit (Aviscera Bioscience, 
Inc). From the results of this measurement, 
data will be obtained in units of ng / mL. 
The examination was carried out at the 
Prodia Laboratory. This study has passed 
the ethical review of the Faculty of 
Medicine, University of Indonesia, number 
953 / UN2.F1 / ETIK / 2017. The research 
data is recorded in the form provided. Data 
will be recorded in the master table, 
verified, edited, coded and analyzed using 
the Stata version 15 program. The statistical 
analysis of the data from this study used 
One Way ANOVA and Kruskal Wallis with 
a significance level of 0.05. 
 
 
3. RESULT 
The results showed that there are 
significant differences in the mean 
gestational age in early onset preeclampsia, 
late onset and normotensive pregnancy in 
the 3rd trimester of pregnancy. The 
differences in mean age, height, BSA, and 
parity were not statistically significant in 
early onset preeclampsia, late onset and 
normotensive pregnancy in the 3rd 
trimester of pregnancy (Table 1). 
	
Table 1. Characteristics of Research Subjects 
 
Characterictic      Early Onset          Late Onset                Control             p value 
Age (years) 31.56 ± 7.47 29.37 ± 6.18 30.23 ± 2.32 0.381 
Height (cm) 154.41 ± 4.76 153.96 ± 4.93 154.58 ± 5.93 0.907 
Weight (kg) 72.89 ± 10.05 79.96 ± 10.14 69.04 ± 5.11 0.286 
BSA (m2) 1.76 ± 0.14 1.74 ± 0.14 1.72 ± 0.08 0.423 
Parity 1.33 ± 1.30 1.11 ± 1.34 1.15 ± 0.54 0.746 
Gestational age 
(weeks) 31.37 ± 1.96 37.81 ± 1.90 38.00 ± 0.00 <0.001 
*BSA: body surface area (m2), One Way ANOVA test, p value < 0.05 
	
Meanwhile, the maternal serum 
concentrations of Endocan in both early 
onset and late onset preeclampsia compared 
to controls are presented in Table 2. The 
results of analysis using Kruskal Wallis 
showed that the difference in Endocan was 
not statistically significant in early onset 
preeclampsia, late onset and normotensive 
pregnancy in the 3rd trimester of 
pregnancy. However, it appears that 
Endocan levels in the two preeclampsia 
groups are relatively the same and higher 
than in normotensive pregnancies. 
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Table 2. Concentrations of Maternal Endocan Serum 
Marker Early Onset Late Onset  Control p value 
Endocan 
(ng/mL) 
37.29 (5.9–263.1) 37.29 (5.9–138.6) 22 (5.09–139) 0.523 
* Kruskal Wallis test, p value < 0.05 
 
	
4. DISCUSSION 
In socio-demographic characteristics of 
the study subjects, there was no significant 
difference between age, height, weight and 
BSA in the three study groups. Body weight 
and BSA, which are thought to have an 
effect on the incidence of preeclampsia, in 
this study did not appear to be significantly 
different in early onset preeclampsia 
compared to late onset, suggesting that 
obesity may not be a risk factor for early 
onset preeclampsia. The results of this 
study differed from the study conducted by 
Iacobelli et al., which stated that there was 
a significant difference between BMI in 
preeclampsia compared to normal controls, 
but there was no difference between early 
onset preeclampsia and late onset 
preeclampsia. Likewise with parity, there 
was no significant difference, indicating 
that parity is not a risk factor for 
preeclampsia. This study is also in line with 
Iacobelli's (Iacobelli et al, 2017). 
Significant differences were only seen at 
gestational age. By definition, early onset 
preeclampsia occurs at <34 weeks' 
gestation (31,37 + 1,96). The results of this 
study refute the old theory that 
preeclampsia is influenced by body weight 
and parity. 
Endocan is a soluble proteoglycan 
secreted by vascular endothelium. 
Proteoglycans (PG) are proteins that have 
glycosaminoglycan chains that are 
covalently related to their protein nuclei. 
Some PG is found in the extracellular 
matrix of connective tissue. Its main 
biological action is to provide structural 
support. Endocan is a type of PG that is 
secreted by vascular endothelium.10 This 
protein has been found to be elevated in 
patients with sepsis, hepatocellular and 
renal malignancies, as well as in other 
inflammatory disorders, such as Behck's 
disease. The endocan may play a key role 
in blood vessels against specific organ 
inflammation and in endothelial dependent 
pathologies, and may also be a marker for 
endothelial cell dysfunction. Endocan 
secretion is regulated by cytokines and 
growth factors, such as Tumor Necrosis 
Factors-α (TNF-α) and Vascular 
Endothelial Growth Factor (VEGF) 
(Iacobelli et al, 2017; Yuksel et al, 2015; 
Kali, 2014). Endocan itself is a marker of 
Glycocalyx disorders (Bar et al, 2019). 
Endocan was first discovered in 1996 
by Lassalle et al. They succeeded in 
identifying a human endothelial cell-
specific molecule (ESM) that was cloned 
from human umbilical vein endothelial 
cells. They also suspect the protein is 
related to cell biology in blood vessels, 
inflammation and lung physiology. 
Because of its very limited distribution in 
vascular endothelial cells, this molecule 
was originally named ESM-1. Subsequent 
research indicated that this ESM-1 
belonged to the proteoglycan group, and 
was later called Endocan (Bar et al, 2019; 
Zhang et al, 2012). 
Endocan can play a role in molecular 
interactions with broad biological activities 
that are important for various biological 
processes such as adhesion, migration, 
proliferation and neovascularization of 
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cells (Kali et al, 2014). In acute infection, 
vascular endothelium and leukocytes will 
express adhesion molecules that play an 
important role in the migration of 
leukocytes out of blood vessels. towards the 
site of infection. Tumor Necrosis Factor 
(TNF) and interleukin-1 (IL-1) secreted by 
macrophages stimulate the expression of 
selectin E and P, as well as other ligand 
integrins such as Intercellular Adhesion 
Molecule-1 (ICAM-1) in the endothelium 
of small blood vessels adjacent to the 
inflamed areas. During the activation 
process of the infection response, 
leukocytes need ligands to bind to E, P and 
integrin selectins, namely Lymphocyte 
Function-Associated Antigen-1 (LFA-1). 
As a result of the binding of the selectin 
with the ligand, circulating leukocytes 
begin to attach to the endothelial surface 
and the LFA-1 bond with ICAM 1 will 
initiate the process of leukocyte 
transmigration to the site of infection in 
peripheral tissues. Endocan core protein 
binding with LFA-1 has a negative effect 
on the interaction of LFA-1 with 
endothelial ICAM-1. As a result, Endocan 
will inhibit leukocyte migration Kali et al, 
2014). 
Although Endocan was first described 
as a soluble circulating dermatan sulfate 
proteoglycan, which is secreted by human 
umbilical vein endothelium, various in 
vitro studies have shown that various 
human endothelial cells also express 
Endocan. Endothelial that is activated due 
to inflammatory processes or due to tumor 
progression will show several-fold increase 
in Endocan mRNA Zhang et al, 2012). 
Endothelial dysfunction, atherosclerosis 
and hypertension are related and since 
Endocan is also associated with endothelial 
dysfunction and inflammation, it is thought 
that Endocan is also associated with 
hypertension (Demirkol et al, 2014; Afsar 
et al, 2014). 
In the pilot study, it was reported that 
the concentration of circulating endocan 
(ESM-1) could be used. as a new marker of 
essential hypertension (Demirkol et al, 
2014). From this study, it was found that in 
18 patients diagnosed with new-onset 
hypertension, serum Endocan 
concentrations were significantly 
associated with carotid artery tunica media 
thickness and were associated with high C 
reactive protein (CRP) levels when 
compared to controls. Other studies have 
shown that Endocan is an endothelial cell-
specific molecule whose expression is 
regulated by cytokines and VEGF (than et 
al, 2008). Zhang et al. study also showed 
that Endocan is expressed in actively 
proliferating cells and tissues, one of which 
is endothelium (Zhang et al, 2012). 
Endocan is not seen in tissue cells that are 
in a silent or resting state, such as the 
splenic endothelium and large arteries 
(Ünal et al, 2017; Demirkol et al, 2014). 
Research Balta et al stated that circulating 
concentrations of Endocan could be used as 
a new marker for hypertension and other 
cardiovascular diseases (Balta et al, 2015). 
The endothelium plays an important 
role in regulating vascular tone and 
maintaining cardiovascular homeostasis by 
releasing various vasoactive factors. In 
addition, endothelial function is also 
affected by systemic inflammation. Since 
hypertension and endothelial dysfunction 
are thought to be associated, Endocan is 
thought to be a new marker that may be 
associated with cardiovascular disease and 
its consequences (Demircioglu et al, 2018). 
So far there have been two studies that 
have examined Endocan levels in 
preeclampsia. The study measured 
Endocan levels in 49 pregnant women with 
preeclampsia and 32 normotensive 
pregnancies (Yuksel et al, 2015). 
Measurement of Endocan levels was 
carried out using an Enzyme Linked 
Immunosorbent Assay (ELISA) kit. The 
study showed no difference in Endocan 
levels between the two study groups (10.7 
± 4.5 vs. 10.3 ± 3.2 ng / mL, p =0.763). 
Other studies have shown that the median 
plasma concentrations of Endocan were 
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higher in the preeclampsia group. 
compared to the normotension group (p = 
0.004), but in the preeclampsia group itself, 
Endocan plasma levels did not differ 
significantly based on the degree of 
severity. 
Endothelial dysfunction is associated 
with sepsis and inflammatory events, 
ranging from vasodilation, edema to 
coagulopathy, ischemia and organ failure. 
Because inflammatory mediators such as 
IL-1 and TNF-α will induce Endocan 
expression, the levels of these 
proteoglycans in the blood will increase, 
and are thought to reflect the severity of the 
inflammation that occurs (kali et al, 2014). 
This is the rationale that serum Endocan 
levels can be used one of the predictor 
markers of preeclampsia. Endocan is 
mainly secreted by inflamed vascular 
endothelial cells. Serum endocan is said to 
be associated with the severity of the 
abnormality that occurs (Lee et al, 2014). In 
this study, endocan levels in maternal 
serum were relatively the same in early 
onset preeclampsia [37.29 (5.9–263.1)] and 
late onset preeclampsia [37.29 (5.9–
138.6)], but their value was relatively 
higher than that of the normotensive 
pregnancy group [22 (5.09–1390], but this 
difference was not statistically significant. 
This is in line with a study conducted by 
Adekola et al which showed that the 
concentration of Endocan in maternal 
plasma was higher in preeclampsia than in 
normotensive pregnancies (p = 0.004) 
(Adekola et al, 2015). In addition, this study 
also stated that there was no significant 
difference in the concentration of maternal 
endocan in preeclampsia that occurred 
before 34 weeks of gestation and or after 34 
weeks. others also showed that serum 
endocan concentrations were significantly 
increased in preeclamptic women 
compared to normotensive (20.04 (12.26) 
ng / mL vs. 15.55 (6.19) ng / mL, p <0.001) 
(Cakmak et al, 2016). 
 
 
5. CONCLUSION 
The results of this study indicate that 
endocan is a promising diagnostic marker 
in preeclampsia, but of course it still 
requires further research with a larger study 
sample and continuous testing starting early 
in pregnancy. 
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